Gonçalves Teixeira, RicardoBrás, Ana RitaCôrte-Real, LeonorTatikonda, RajendhraprasadSanches, AnabelaRobalo, Maria PaulaAvecilla, FernandoMoreira, TiagoGarcia, M. HelenaHaukka, MattiPreto, AnaValente, Andreia2017-12-072017-12-072017-12-02TEIXEIRA, Ricardo G.; [et al] – Novel ruthenium methylcyclopentadienyl complex bearing a bipyridine perfluorinated ligand shows strong activity towards colorectal cancer cells. European Journal of Medicinal Chemistry. ISSN: 0223-5234. Vol. 143, (2017), pp. 503-514.0223-5234http://hdl.handle.net/10400.21/7669Three new compounds have been synthesized and completely characterized by analytical and spectroscopic techniques. The new bipyridine-perfluorinated ligand L1 and the new organometallic complex [Ru(η5-MeCp)(PPh3)2Cl] (Ru1) crystalize in the centrosymmetric triclinic space group P <img height="13" border="0" style="vertical-align:bottom" width="11" alt="View the MathML source" title="View the MathML source" src="http://origin-ars.els-cdn.com/content/image/1-s2.0-S0223523417309625-si1.gif">1¯. Analysis of the phenotypic effects induced by both organometallic complexes Ru1 and [Ru(η5-MeCp)(PPh3)(L1)][CF3SO3] (Ru2), on human colorectal cancer cells (SW480 and RKO) survival, showed that Ru2 has a potent anti-proliferative activity, 4–6 times higher than cisplatin, and induce apoptosis in these cells. Data obtained in a noncancerous cell line derived from normal colon epithelial cells (NCM460) revealed an intrinsic selectivity of Ru2 for malignant cells at low concentrations, showing the high potential of this compound as a selective anticancer agent.engRuthenium methylcyclopentadienylColorectal cancerApoptosisSelectivityjournal articlehttps://doi.org/10.1016/j.ejmech.2017.11.059